Jun. 2 at 10:16 AM
$WVE Bull Case:
The market is still sleeping on Wave. DMD NDA submission is expected in H2 2026, and if ongoing discussions with the FDA go well, AATD could potentially reach NDA submission by late 2026 as well.
That sets up the possibility of TWO major PDUFA catalysts in 2027.
Meanwhile, the company has over
$500M in cash, significantly reducing financing risk. Institutions recently backed a large offering at
$19/share, yet the stock is currently trading below that level.
Two late-stage assets, a strong balance sheet, multiple regulatory catalysts, and a valuation that still doesn’t reflect the potential upside.
Risk/reward looks very attractive from here.
